A clean mechanism, a forty-year-old evidence base, and the reverse of the result you would want: strongest in good sleepers, weakest in chronic insomnia.
One researcher published two studies on DSIP for insomnia. They reached almost opposite conclusions. The difference between them is the single most useful thing on this page.
The open study. Seven patients with severe insomnia, ten injections. Sleep normalised in six of seven, with benefits holding for three to seven months afterwards. Daytime mood and performance improved too. On its face, a remarkable result.
The controlled study. Sixteen chronic insomniacs, DSIP against placebo, five nights. Sleep efficiency was higher and people fell asleep sooner. But the effects were weak. Schneider-Helmert's own conclusion was that short-term DSIP for chronic insomnia is unlikely to be of much therapeutic benefit.
Same compound. Same condition. Same investigator. The open study had no placebo arm; the controlled one did.
That is what a control group does. It does not make an effect disappear. It separates what comes from the compound from what comes from expecting the compound to work. Sleep is unusually open to that, because how well you slept is partly a judgement you make in the morning.
Anyone who read the thymosin alpha-1 sepsis data will recognise the shape. There, a significant pooled benefit vanished once the weak trials were excluded. This is the same lesson in miniature, and it is unusually clean because the two studies come from the same hand.
The source material states this plainly, rather than quoting the good number and dropping the bad one. That is more than most write-ups on this compound manage.
DSIP is nine amino acids:
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Schoenenberger and Monnier isolated it in 1977. They drew it from blood leaving the brains of rabbits held in slow-wave sleep by electrical stimulation, and named it for the delta waves that mark the deepest stage. Your hypothalamus makes it, and it crosses into the brain readily.
Two pushes in the same direction.
GABA up. It potentiates your main inhibitory neurotransmitter — the same target benzodiazepines hit, without the dependency or cognitive cost.
Glutamate down. It blocks NMDA receptors, damping the excitatory signalling that keeps you alert.
Turn down wakefulness while turning up calm. As mechanisms for a sleep compound go, that is about as clean as it gets.
There is more. It modulates cortisol through the HPA axis, which matters because raised night-time cortisol is a common reason people lie awake. It influences serotonin and melatonin release. And it engages opioid receptors, which is where the pain and withdrawal findings come from. In animals its slow-wave effect was reversed by naloxone, the opioid blocker, which is direct evidence for that pathway.
And this is exactly the trap this site keeps documenting. A plausible mechanism plus a weak controlled result is not a contradiction — it is the normal situation. Mechanisms tell you a compound could work. Only controlled trials tell you whether it does.
Here is what stands out when you rank the human evidence by size rather than by relevance to the compound's name.
Dick and colleagues, 1984. 107 patients in detoxification, 60 opioid-dependent and 47 alcohol-dependent. Withdrawal symptoms eased in 97% of the opioid group and 87% of the alcohol group, covering both physical symptoms and anxiety. Tolerability was good apart from headaches in a few patients.
That is a far larger sample and a far bigger effect than anything in this compound's sleep literature. It was uncontrolled, so the same caution applies as to the open insomnia study. But it is worth noticing that the best human result for the delta sleep inducing peptide is about opioid and alcohol withdrawal.
Larbig's work the same year found reduced pain and improved mood in patients with chronic severe pain, some of whom cut back on pain medication.
The double-blind crossover (Schneider-Helmert and Schoenenberger, 1983). Six healthy volunteers, intravenous. Immediate sleep pressure reported, total sleep time up 59% within a 130-minute window, and the following night showed faster onset and better efficiency.
One detail beats the headline number. There was no sedation in the usual drug sense. They were not knocked out. That supports the claim that DSIP works with sleep architecture rather than overriding it. It also does not suppress REM, which most conventional sleep drugs do.
Six people, healthy, in a lab. Suggestive, and small.
Put the sleep evidence together and one reading holds up: it may do more for decent sleep than for broken sleep. The strongest result came from healthy volunteers. The weakest came from chronic insomniacs. That is the reverse of how most people would want it to go, and it is the honest way round.
The plasma half-life is roughly 7 to 15 minutes, because enzymes dismantle it quickly. It may bind to carrier proteins in the body, which would stretch how long it stays useful.
Anyone who read the Selank article will recognise this: minutes of exposure, hours of effect. It comes up so often in this field that it is worth stating as a rule. Half-life tells you how long a molecule is present. It does not tell you how long its effect lasts.
A consistent thread in user reports, and unusual enough to flag: higher doses can make sleep worse. Grogginess the next day, sleepiness extending into the following afternoon, and in some reports disrupted sleep rather than improved sleep.
That is a real dose-response inversion, not the usual "watch for side effects" line. Whatever the mechanism, the ceiling here is low, and pushing past it works against you.
Individual variation is wide too. Some people report a clear difference, others nothing at all. That is what you would expect from a compound whose controlled trial found weak effects.
Both come from the source, and both are about diagnosing before treating.
With growth hormone peptides. GH secretagogues can disrupt sleep, especially in the first few weeks — that is a documented pattern, not a rumour. Using DSIP at night to offset a compound taken for its daytime effects is coherent reasoning. It is one of the few stacking arguments in this field that names a real problem before proposing a fix.
With GLP-1 agonists. The source makes a point I have not seen elsewhere and it deserves repeating. If you are on a GLP-1 and sleeping badly, appetite suppression may mean you are undereating, and overnight blood sugar crashes wake people up. That is a nutrition problem dressed as a sleep problem, and no peptide fixes it.
The same logic runs wider. If your schedule only allows five hours, the constraint is the schedule. DSIP cannot widen a sleep window you have not left open.
The 1980s studies reported a favourable profile: no dependency, no tolerance, no rebound insomnia, no respiratory depression, and no impairment of memory consolidation. The 107-patient withdrawal trial noted only headaches in a few people.
The caveat is the same one that applies to every result here. These were short studies with small samples, run four decades ago. No modern randomised controlled trial exists. Absence of harm in that record is not the same as an established long-term safety profile.
Reported effects are mild: headache, grogginess if the dose is too high, some mood variability, and vivid dreams — frequently enough reported to expect rather than be surprised by. A few people describe brief anxiety. Some find sleep temporarily worse after stopping prolonged daily use, which is adaptation rather than withdrawal, but is a reason not to run it indefinitely.
No safety data in pregnancy or breastfeeding.
Two interactions follow straight from the mechanism. Other sedatives, benzodiazepines and sleep medicines, because GABA potentiation stacks and heavy sedation is the predictable result. And opioid medicines, because DSIP engages the same receptor system. The naloxone result in animals shows that pathway is real, not theoretical.
Care also with kidney or liver impairment, given clearance.
And one honest exclusion. Severe chronic insomnia is where the controlled evidence is weakest. That is not a safety warning. It marks the group most likely to be disappointed, and it is also the group most likely to go looking.
The FDA classified DSIP as a Category 2 bulk drug substance in 2024, closing it to compounding pharmacies.
Worth setting against thymosin alpha-1, which came off that list in September of the same year. Two compounds crossing in opposite directions in a single year. The difference is what was in the file. On one side, 11,000 subjects across more than 30 modern trials. On the other, a handful of small studies from the 1980s.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
Licensed in Russia since 2009, with human trials matching a benzodiazepine without the sedation. Nearly all of the evidence comes from a single research tradition — and the route you use changes the pharmacology.
